Treating hyperuricemia of gout: Safety and efficacy of febuxostat and allopurinol in older versus younger subjects

Nucleosides, Nucleotides and Nucleic Acids

Volumn 30, Issue 12, 2011, Pages 1011-1017

  Becker, Michael A ^a   Macdonald, Patricia A ^b   Hunt, Barbara ^b   Gunawardhana, Lhanoo ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

Author keywords

Allopurinol; Elderly; Febuxostat; Gout; Hyperuricemia

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; URATE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GOUT; GROUPS BY AGE; HUMAN; HYPERURICEMIA; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ALLOPURINOL; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; THIAZOLES; TREATMENT OUTCOME; URIC ACID;

EID: 84855888370     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770.2011.603715     Document Type: Article

References (17)

1. Wallace, K. L.; Riedel, A. A.; Joseph-Ridge, N.; Wortmann, R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J. Rheumatol. 2004, 31(8), 1582-1587. (Pubitemid 39006641)
2. Lawrence, R. C.; Felson, D. T.; Helmick, C. G.; Arnold, L. M.; Choi, H.; Deyo, R. A.; Gabriel, S.; Hirsch, R.; Hochberg, M. C.; Hunder, G. G.; Jordan, J. M.; Katz, J. N.; Kremers, H. M.; Wolfe, F. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis. Rheum. 2008, 58(1), 26-35.
3. Cea-Soriano, L.; Rothenbacher, D.; Choi, H. K.; Garcia Rodriguez, L. A. Contemporary epidemiology of gout in the UK general population. Arthritis. Res. Ther. 2011, 13(2), R39.
4. Hanly, J. G.; Skedgel, C.; Sketris, I.; Cooke, C.; Linehan, T.; Thompson, K.; van Zanten, S. V. Gout in the elderly-a population health study. J. Rheumatol. 2009, 36(4), 822-830.
5. Wu, E. Q.; Patel, P. A.; Yu, A. P.; Mody, R. R.; Cahill, K. E.; Tang, J.; Krishnan, E. Disease-related and all-cause health care costs of elderly patients with gout. J. Manag. Care Pharm. 2008, 14(2), 164-175. (Pubitemid 351453817)
6. Choi, H. K.; Atkinson, K.; Karlson, E. W.; Curhan, G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch. Intern. Med. 2005, 165(7), 742-748. (Pubitemid 40569426)
7. Grodzicki, T.; Palmer, A.; Bulpitt, C. J. Incidence of diabetes and gout in hypertensive patients during 8 years of follow-up. The general practice hypertension study group. J. Hum. Hypertens. 1997, 11(9), 583-585. (Pubitemid 27478542)
8. Hunter, D. J.; York, M.; Chaisson, C. E.; Woods, R.; Niu, J.; Zhang, Y. Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J. Rheumatol. 2006, 33(7), 1341-1345. (Pubitemid 44026423)
9. Becker, M. A.; Schumacher, H. R.; Espinoza, L. R.; Wells, A. F.; MacDonald, P.; Lloyd, E.; Lademacher, C. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis. Res. Ther. 2010, 12(2), R63.
10. Sarawate, C. A.; Brewer, K. K.; Yang, W.; Patel, P. A.; Schumacher, H. R.; Saag, K. G.; Bakst, A. W. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo. Clin. Proc. 2006, 81(7), 925-934. (Pubitemid 43993484)
11. Levey, A. S.; Stevens, L. A.; Schmid, C. H.; Zhang, Y. L.; Castro, A. F. 3rd.; Feldman, H. I.; Kusek, J. W.; Eggers, P.; Van Lente, F.; Greene, T.; Coresh, J. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 2009, 150(9), 604-612.
12. Whelton, A. Current and future therapeutic options for the management of gout. Am. J. Ther. 2010, 17(4), 402-417.
13. Whelton, A.; Macdonald, P. A.; Zhao, L.; Hunt, B.; Gunawardhana, L. Renal function in gout: longterm treatment effects of febuxostat. J. Clin. Rheumatol. 2011, 17(1), 7-13.
14. Gibson, T.; Rodgers, V.; Potter, C.; Simmonds, H. A. Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann. Rheum. Dis. 1982, 41(1), 59-65. (Pubitemid 12136653)
15. Choi, H. K.; Curhan, G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007, 116(8), 894-900. (Pubitemid 47300913)
16. Colvine, K.; Kerr, A. J.; McLachlan, A.; Gow, P.; Kumar, S.; Ly, J.; Wiltshire, C.; Robinson, E.; Dalbeth, N. Cardiovascular disease risk factor assessment and management in gout: an analysis using guidelinebased electronic clinical decision support. N. Z. Med. J. 2008, 121(1285), 73-81.
17. Holme, I.; Aastveit, A. H.; Hammar, N.; Jungner, I.; Walldius, G. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417, 734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J. Intern. Med. 2009, 266(6), 558-570.